BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value
$416.54+0.58 (+0.14%)
Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –
BeOne Medicines cash
Cash and short-term investments held at the end of each period.
BeOne Medicines's cash was $5.78B at Sep 30, 2026. For fiscal 2025 it was $4.55B, up 72.3% from the year before. Over ten years it grew 46.4% a year on average. The highest annual figure on record is $6.62B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.55B | +72.3% |
| FY2024 | Dec 31, 2024 | $2.64B | -16.9% |
| FY2023 | Dec 31, 2023 | $3.17B | -30.1% |
| FY2022 | Dec 31, 2022 | $4.54B | -31.5% |
| FY2021 | Dec 31, 2021 | $6.62B | +42.2% |
| FY2020 | Dec 31, 2020 | $4.66B | +372.7% |
| FY2019 | Dec 31, 2019 | $985.50M | -45.5% |
| FY2018 | Dec 31, 2018 | $1.81B | +116.0% |
| FY2017 | Dec 31, 2017 | $837.52M | +127.5% |
| FY2016 | Dec 31, 2016 | $368.17M | +266.4% |
| FY2015 | Dec 31, 2015 | $100.49M | +623.0% |
| FY2014 | Dec 31, 2014 | $13.90M | +254.0% |
| FY2013 | Dec 31, 2013 | $3.93M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.78B | +43.2% |
| Q2 FY2026 | Jun 30, 2026 | $5.10B | +85.0% |
| Q1 FY2026 | Mar 31, 2026 | $4.79B | +90.4% |
| Q4 FY2025 | Dec 31, 2025 | $4.55B | +72.3% |
| Q3 FY2025 | Sep 30, 2025 | $4.04B | +49.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.76B | +6.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.52B | -9.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.64B | -16.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.70B | -11.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.59B | -24.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.79B | -21.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.17B | -30.1% |
| Q3 FY2023 | Sep 30, 2023 | $3.07B | -26.9% |
| Q2 FY2023 | Jun 30, 2023 | $3.41B | -24.7% |
| Q1 FY2023 | Mar 31, 2023 | $3.54B | -43.3% |
| Q4 FY2022 | Dec 31, 2022 | $4.54B | -31.5% |
| Q3 FY2022 | Sep 30, 2022 | $4.20B | +7.2% |
| Q2 FY2022 | Jun 30, 2022 | $4.53B | +3.4% |
| Q1 FY2022 | Mar 31, 2022 | $6.24B | +29.8% |
| Q4 FY2021 | Dec 31, 2021 | $6.62B | +42.2% |
| Q3 FY2021 | Sep 30, 2021 | $3.92B | -17.0% |
| Q2 FY2021 | Jun 30, 2021 | $4.38B | +39.0% |
| Q1 FY2021 | Mar 31, 2021 | $4.81B | +42.6% |
| Q4 FY2020 | Dec 31, 2020 | $4.66B | +372.7% |
| Q3 FY2020 | Sep 30, 2020 | $4.72B | +282.8% |
| Q2 FY2020 | Jun 30, 2020 | $3.15B | +105.0% |
| Q1 FY2020 | Mar 31, 2020 | $3.37B | +109.1% |
| Q4 FY2019 | Dec 31, 2019 | $985.50M | -45.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.23B | -39.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.54B | +12.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.61B | +10.2% |
| Q4 FY2018 | Dec 31, 2018 | $1.81B | +116.0% |
| Q3 FY2018 | Sep 30, 2018 | $2.03B | +168.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.37B | +236.2% |
| Q1 FY2018 | Mar 31, 2018 | $1.46B | +347.1% |
| Q4 FY2017 | Dec 31, 2017 | $837.52M | +127.5% |
| Q3 FY2017 | Sep 30, 2017 | $757.44M | – |
| Q2 FY2017 | Jun 30, 2017 | $407.43M | – |
| Q1 FY2017 | Mar 31, 2017 | $327.48M | – |
| Q4 FY2016 | Dec 31, 2016 | $368.17M | – |
See a number that looks wrong?